Xinguang Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Xinguang Chen has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Fengxiang Zhang
Section of Pacing and Electrophysiology, Division of Cardiology, The First Affiliated Hospital of Nanjing Medical University, Guangzhou Road 300, Nanjing 210029, China
2 shared publications Chen-Xi Yang
Department of Cardiology, The Fifth People’s Hospital of Shanghai, Fudan University, Shanghai, China
1 shared publication- Gao-Feng Zhang
Department of Cardiology, Shanghai Fifth People's Hospital, Fudan University, Shanghai, 200240, China
1 shared publication Houdeng Yu
Division of Cardiology, The First Affiliated Hospital of Gannan Medical University, Ganzhou, China
1 shared publication- Jing Jin
Department of Cardiology, The Fifth People’s Hospital of Shanghai, Fudan University, Shanghai, China
1 shared publication - Kai-Yue Han
Department of Cardiology, The Fifth People’s Hospital of Shanghai, Fudan University, Shanghai, China
1 shared publication
Latest Publications
- Open Access
- 29 October 2025
- Published by IMR Press in Reviews in Cardiovascular Medicine
- Vol. 26 (10)
Long-Term Efficacy of Catheter Ablation for Atrial Fibrillation in Different Phenotypes of Hypertrophic Cardiomyopathy
Background: Atrial fibrillation catheter ablation (AFCA) success rates vary across different phenotypes of hypertrophic cardiomyopathy (HCM). Therefore, we compared long-term outcomes between apical (aHCM) and septal (sHCM) subtypes of HCM. Methods: This retrospective study analyzed patients with HCM who underwent AFCA at the First Affiliated Hospital of Nanjing Medical University between January 2010 and December 2020. Results: A total of 36 patients with aHCM and 80 patients with sHCM were enrolled. During a median follow-up of 42 months (interquartile range (IQR) 18–83), the overall atrial tachyarrhythmia (ATa) recurrence rate after a single ablation was 42.2% (49/116). The aHCM patients had a higher ATa recurrence rate than the sHCM patients (58.3% vs. 35.0%; χ2 = 5.54; p = 0.019). The ATa recurrence risk increased by 94% in patients with aHCM (hazard ratio (HR) 1.94, 95% confidence interval (CI) 1.10–3.43; log-rank p = 0.021). Subgroup analysis demonstrated pronounced risk elevation in paroxysmal atrial fibrillation (AF) patients (HR 2.85, 95% CI 1.44–5.67; p = 0.003), while no intergroup difference was observed in patients with persistent AF (HR 0.90, 95% CI 0.31–2.62; p = 0.853) (interaction p = 0.080). Multivariate Cox regression analysis identified antiarrhythmic drug (AAD) use (HR 0.22, 95% CI 0.08–0.59; p = 0.003), hypertension comorbidity (HR 2.50, 95% CI 1.21–5.19; p = 0.014), persistent AF type (HR 0.41, 95% CI 0.17–1.00; p = 0.049), and left atrial diameter ≥45 mm (HR 2.55, 95% CI 1.11–5.85; p = 0.028) as independent predictors of postoperative recurrence. Conclusions: An aHCM subtype predicts higher ATa recurrence after a single ablation versus sHCM. Hypertension, a left atrial enlargement ≥45 mm, and no AAD use are independent predictors of recurrence. Meanwhile, optimizing blood pressure and AAD therapy may improve outcomes.
- 29 October 2025
- Published by IMR Press in Reviews in Cardiovascular Medicine
- Vol. 26 (10)
Open AccessLong-Term Efficacy of Catheter Ablation for Atrial Fibrillation in Different Phenotypes of Hypertrophic Cardiomyopathy
Background: Atrial fibrillation catheter ablation (AFCA) success rates vary across different phenotypes of hypertrophic cardiomyopathy (HCM). Therefore, we compared long-term outcomes between apical (aHCM) and septal (sHCM) subtypes of HCM. Methods: This retrospective study analyzed patients with HCM who underwent AFCA at the First Affiliated Hospital of Nanjing Medical University between January 2010 and December 2020. Results: A total of 36 patients with aHCM and 80 patients with sHCM were enrolled. During a median follow-up of 42 months (interquartile range (IQR) 18–83), the overall atrial tachyarrhythmia (ATa) recurrence rate after a single ablation was 42.2% (49/116). The aHCM patients had a higher ATa recurrence rate than the sHCM patients (58.3% vs. 35.0%; χ2 = 5.54; p = 0.019). The ATa recurrence risk increased by 94% in patients with aHCM (hazard ratio (HR) 1.94, 95% confidence interval (CI) 1.10–3.43; log-rank p = 0.021). Subgroup analysis demonstrated pronounced risk elevation in paroxysmal atrial fibrillation (AF) patients (HR 2.85, 95% CI 1.44–5.67; p = 0.003), while no intergroup difference was observed in patients with persistent AF (HR 0.90, 95% CI 0.31–2.62; p = 0.853) (interaction p = 0.080). Multivariate Cox regression analysis identified antiarrhythmic drug (AAD) use (HR 0.22, 95% CI 0.08–0.59; p = 0.003), hypertension comorbidity (HR 2.50, 95% CI 1.21–5.19; p = 0.014), persistent AF type (HR 0.41, 95% CI 0.17–1.00; p = 0.049), and left atrial diameter ≥45 mm (HR 2.55, 95% CI 1.11–5.85; p = 0.028) as independent predictors of postoperative recurrence. Conclusions: An aHCM subtype predicts higher ATa recurrence after a single ablation versus sHCM. Hypertension, a left atrial enlargement ≥45 mm, and no AAD use are independent predictors of recurrence. Meanwhile, optimizing blood pressure and AAD therapy may improve outcomes.
- Open Access
- 1 January 2024
- Published by Wiley in Cardiology Research and Practice
- Vol. 2024 (1) , 3672210
Validation Strategy for Pulmonary Vein Isolation in Patients With Paroxysmal Atrial Fibrillation in Long‐Term Maintaining Sinus Rhythm: A Randomized Controlled Study
Background: Data comparing the outcomes of loose versus rigorous validation strategies for pulmonary vein isolation (PVI) in patients with paroxysmal atrial fibrillation (PAF) are limited. We aimed to prospectively assess the effectiveness of loose versus rigorous validation for PVI in patients with PAF with a maintained sinus rhythm.Methods: Patients (n = 117) with PAF were randomized to receive either loose validation (n = 59) or rigorous validation (n = 58) after PVI. The presence of dormant conduction in loose validation was assessed only by adenosine administration followed by isoproterenol infusion. The complete absence of pulmonary vein (PV) potentials in rigorous validation was confirmed by the combination of the Lasso catheter with isoproterenol plus adenosine. Dormant conduction, revealed by validation after PVI, was ablated until all reconnections were eliminated.Results: The procedure time in the rigorous validation group was greater than that in the loose validation group (161.3 ± 52.7 min vs. 142.5 ± 37.6 min, p = 0.03, respectively). After successful PVI, the detection of dormant PV reconnections in the rigorous validation group was significantly greater than that in the loose validation group (69.0% vs. 37.3%, p = 0.001). However, after reisolation of the sites of dormant PV conduction, the postablation recurrence rates in 1.3 years were similar between the groups (79.2% vs. 83.6%, p = 0.67).Conclusion: Rigorous validation can reveal dormant conduction in more than two‐thirds of patients with PAF undergoing PVI. However, rigorous validation and additional ablation of the resulting connections do not improve long‐term outcomes when a protocol that includes electrophysiological confirmation and pharmacological validation is used.
- 1 January 2024
- Published by Wiley in Cardiology Research and Practice
- Vol. 2024 (1) , 3672210
Open AccessValidation Strategy for Pulmonary Vein Isolation in Patients With Paroxysmal Atrial Fibrillation in Long‐Term Maintaining Sinus Rhythm: A Randomized Controlled Study
Background: Data comparing the outcomes of loose versus rigorous validation strategies for pulmonary vein isolation (PVI) in patients with paroxysmal atrial fibrillation (PAF) are limited. We aimed to prospectively assess the effectiveness of loose versus rigorous validation for PVI in patients with PAF with a maintained sinus rhythm.Methods: Patients (n = 117) with PAF were randomized to receive either loose validation (n = 59) or rigorous validation (n = 58) after PVI. The presence of dormant conduction in loose validation was assessed only by adenosine administration followed by isoproterenol infusion. The complete absence of pulmonary vein (PV) potentials in rigorous validation was confirmed by the combination of the Lasso catheter with isoproterenol plus adenosine. Dormant conduction, revealed by validation after PVI, was ablated until all reconnections were eliminated.Results: The procedure time in the rigorous validation group was greater than that in the loose validation group (161.3 ± 52.7 min vs. 142.5 ± 37.6 min, p = 0.03, respectively). After successful PVI, the detection of dormant PV reconnections in the rigorous validation group was significantly greater than that in the loose validation group (69.0% vs. 37.3%, p = 0.001). However, after reisolation of the sites of dormant PV conduction, the postablation recurrence rates in 1.3 years were similar between the groups (79.2% vs. 83.6%, p = 0.67).Conclusion: Rigorous validation can reveal dormant conduction in more than two‐thirds of patients with PAF undergoing PVI. However, rigorous validation and additional ablation of the resulting connections do not improve long‐term outcomes when a protocol that includes electrophysiological confirmation and pharmacological validation is used.
- Open Access
- 12 March 2021
- Published by Hindawi Limited in Cardiology Research and Practice
- Vol. 2021, 1-7
Atrial Arrhythmias in Patients with Severe COVID-19
The number of confirmed COVID-19 cases has increased drastically; however, information regarding the impact of this disease on the occurrence of arrhythmias is scarce. The aim of this study was to determine the impact of COVID-19 on arrhythmia occurrence. This prospective study included patients with COVID-19 treated at the Leishenshan Temporary Hospital of Wuhan City, China, from February 24 to April 5, 2020. Demographic, comorbidity, and arrhythmias data were collected from patients with COVID-19 (n = 84) and compared with control data from patients with bacterial pneumonia (n = 84) infection. Furthermore, comparisons were made between patients with severe and nonsevere COVID-19 and between older and younger patients. Compared with patients with bacterial pneumonia, those with COVID-19 had higher total, mean, and minimum heart rates (all ). Patients with severe COVID-19 (severe and critical type diseases) developed more atrial arrhythmias compared with those with nonsevere symptoms. Plasma creatine kinase isoenzyme (CKMB) levels ( ) were higher in the severe group than in the nonsevere group, and there were more deaths in the severe group than in the nonsevere group (6 (15%) vs. 3 (2.30%); ). Premature atrial contractions (PAC) and nonsustained atrial tachycardia (NSAT) were significantly positively correlated with plasma CKMB levels but not with high-sensitive cardiac troponin I or myoglobin levels. Our data demonstrate that COVID-19 patients have higher total, mean, and minimum heart rates compared with those with bacterial pneumonia. Patients with severe or critical disease had more frequent atrial arrhythmias (including PAC and AF) and higher CKMB levels and mortality than those with nonsevere symptoms.
- 12 March 2021
- Published by Hindawi Limited in Cardiology Research and Practice
- Vol. 2021, 1-7
Open AccessAtrial Arrhythmias in Patients with Severe COVID-19
The number of confirmed COVID-19 cases has increased drastically; however, information regarding the impact of this disease on the occurrence of arrhythmias is scarce. The aim of this study was to determine the impact of COVID-19 on arrhythmia occurrence. This prospective study included patients with COVID-19 treated at the Leishenshan Temporary Hospital of Wuhan City, China, from February 24 to April 5, 2020. Demographic, comorbidity, and arrhythmias data were collected from patients with COVID-19 (n = 84) and compared with control data from patients with bacterial pneumonia (n = 84) infection. Furthermore, comparisons were made between patients with severe and nonsevere COVID-19 and between older and younger patients. Compared with patients with bacterial pneumonia, those with COVID-19 had higher total, mean, and minimum heart rates (all ). Patients with severe COVID-19 (severe and critical type diseases) developed more atrial arrhythmias compared with those with nonsevere symptoms. Plasma creatine kinase isoenzyme (CKMB) levels ( ) were higher in the severe group than in the nonsevere group, and there were more deaths in the severe group than in the nonsevere group (6 (15%) vs. 3 (2.30%); ). Premature atrial contractions (PAC) and nonsustained atrial tachycardia (NSAT) were significantly positively correlated with plasma CKMB levels but not with high-sensitive cardiac troponin I or myoglobin levels. Our data demonstrate that COVID-19 patients have higher total, mean, and minimum heart rates compared with those with bacterial pneumonia. Patients with severe or critical disease had more frequent atrial arrhythmias (including PAC and AF) and higher CKMB levels and mortality than those with nonsevere symptoms.